Exploiting Natural Killer Cell Engagers to Control Pediatric B Cell Precursor Acute Lymphoblastic Leukemia

Researchers tested the in vitro effect of different natural killer (NK)-cell engagers, which triggered either NKp46 or NKp30 together with CD16A, and targeted either CD19 or CD20 to induce killing of pediatric B cell precursor acute lymphoblastic leukemia.